Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Efficacy of REHACOP Program in Schizophrenia (CSrehacopSZ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02796417
Recruitment Status : Completed
First Posted : June 10, 2016
Last Update Posted : June 10, 2016
Sponsor:
Information provided by (Responsible Party):
University of Deusto

Brief Summary:
This study examined the efficacy of an integrative cognitive remediation program (REHACOP) to improve cognition, social cognition, clinical symptoms and functional outcome in patients with schizophrenia.

Condition or disease Intervention/treatment Phase
Schizophrenia Behavioral: REHACOP Behavioral: Occupational activities Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 111 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Implementation of REHACOP Cognitive Training Program in Schizophrenia
Study Start Date : March 2012
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: Rehacop group
Cognitive rehabilitation
Behavioral: REHACOP
REHACOP group consists of 90-minute-long sessions 3 days per week. Specifically, REHACOP group remediation consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas

Active Comparator: Control group
Occupational activities
Behavioral: Occupational activities
Occupational group activities conducted included drawing, gardening, reading the daily news and constructing using different materials (such as paper or wood).




Primary Outcome Measures :
  1. Change in functional competence after receiving cognitive remediation [ Time Frame: 4 months ]
    functional competence was measured with San Diego UCSD Performance-Based Skills Assessment- UPSA

  2. Change in global functioning after receiving cognitive remediation [ Time Frame: 4 months ]
    global functioning measured with Global Assessment of Functioning (GAF)

  3. change in verbal memory after receiving cognitive remediation [ Time Frame: 4 months ]
    Verbal memory performance was assessed with the Hopkins Verbal Learning Test-HVLT (Brandt and Benedict 2001)

  4. change in processing speed after receiving cognitive remediation [ Time Frame: 4 months ]
    Processing speed was assessed with Digit Symbol subtest from Wechsler Adult Intelligence Scale-III (Wechsler 1997)


Secondary Outcome Measures :
  1. change in emotion perception after receiving cognitive remediation [ Time Frame: 4 months ]
    emotion perception was assessed with Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT)

  2. change in clinical symptoms after receiving cognitive remediation [ Time Frame: 4 months ]
    Clinical symptoms was measured with Positive and Negative Syndrome Scale (PANSS)

  3. change in social perception after receiving cognitive remediation [ Time Frame: 4 months ]
    Social perception was assessed with the Social Featuring Recognition Test (SFRT)

  4. change in theory of mind after receiving cognitive remediation [ Time Frame: 4 months ]
    Theory of mind was assessed with Happe Strange Stories Test



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnostic criteria for Schizophrenia according to American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

Exclusion Criteria:

  • evidence of alcohol or drug abuse in the last 30 days
  • previous history of significant lack of consciousness
  • mental retardation
  • relevant neurological or medical condition

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02796417


Locations
Layout table for location information
Spain
University of Deusto
Bilbao, Biskai, Spain, 48007
Sponsors and Collaborators
University of Deusto
Investigators
Layout table for investigator information
Principal Investigator: Natalia Ojeda, PhD Universidad de Deusto

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Deusto
ClinicalTrials.gov Identifier: NCT02796417     History of Changes
Other Study ID Numbers: NSMC-003-UD
First Posted: June 10, 2016    Key Record Dates
Last Update Posted: June 10, 2016
Last Verified: June 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders